Compare VAC & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VAC | VERA |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | 2011 | 2021 |
| Metric | VAC | VERA |
|---|---|---|
| Price | $120.80 | $31.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $75.13 | ★ $81.30 |
| AVG Volume (30 Days) | 492.4K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.82 | N/A |
| Revenue | ★ $5,032,000,000.00 | N/A |
| Revenue This Year | $54.23 | N/A |
| Revenue Next Year | $2.90 | $472.48 |
| P/E Ratio | $43.02 | ★ N/A |
| Revenue Growth | ★ 1.31 | N/A |
| 52 Week Low | $44.58 | $21.15 |
| 52 Week High | $131.34 | $56.05 |
| Indicator | VAC | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 66.83 | 42.98 |
| Support Level | $65.76 | $30.07 |
| Resistance Level | $131.34 | $32.44 |
| Average True Range (ATR) | 5.67 | 1.75 |
| MACD | 1.73 | -0.12 |
| Stochastic Oscillator | 70.49 | 46.20 |
Marriott Vacations Worldwide Corp functions in the United States leisure industry. It owns and manages a cluster of resorts and accommodation facilities under trademarks like Marriott Vacation Club, Grand Residencies, and The Ritz-Carlton Destination Club predominantly in the United States. Some of its properties are also spread across Europe and Asia Pacific. Marriott's majority revenue components include the sale of vacation ownership products such as luxurious vacation packages. In addition, it offers purchase money financing to the end users of its core services. The company operates in two reportable segments: Vacation Ownership and Exchange & Third-Party Management. The majority of revenue is derived from the Vacation Ownership segment.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.